BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study, designed to generate critical data to support evaluation of the safety and tolerability ...

This Phase I dose-escalation study in patients with advanced solid tumors was performed to determine the MTD, overall safety, pharmacokinetic (PK) profile and anti-tumor activity of afatinib ...

Advancing to this final dose escalation reaffirms Portage's confidence in the safety and therapeutic potential of PORT-6, bringing the Company closer to identifying an optimal dose range for further ...

OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. Discontinue if concurrent opioid pain medication is also discontinued.

This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with metastatic or unresectable solid tumors including non-small cell lung cancer (NSCLC). Bolt will ...